Delays disease progressionThe time to radiographic progression doubled in men treated with Abiraterone and Prednisone versus Prednisone alone at 16.5 versus 8.3 months.
Improves survivalOverall Survival (OS) improved by 5 months in the Abiraterone arm.
Extends time with minimal or no symptoms69% of patients had at least a 50% decline in PSA levels with Abiraterone.
ZYTIX Plus Prednisone show improvements in asymptomatic or mildly symptomatic chemotherapy-naive patients with metastatic castration-resistant Prostate Cancer
The First and Only Selective Androgen Biosynthesis Inhibitor
Abiraterone Acetate 250 mg tablet
sttime inBangladesh
L i g h t f o r l i f e
L i g h t f o r l i f e
Provides longer survival time
Ensures patient convenience
Manages patient in superior manner
Offers better tolerability
The First Choice for Antiandrogen therapy
icalBicalutamide USP 50 mg Tablet
albumin
Paclitaxel
L i g h t f o r l i f e
Advantages of Nab-Paclitaxel over conventional Paclitaxel
elpacNab-Nab-Paclitaxel 100 mg Injection
Targeting the Heart of the Tumor
Increased intratumor Paclitaxel concentrations (33% higher)
53% higher volume of distribution compared to Paclitaxel injection
Shorter infusion time is needed (30 min vs 3 hours)
Maximum tolerated dose is 300 mg/m2 (70% higher dose administration is feasible than conventional Paclitaxel)
Premedications are not required NanoTechnology
Deliv
erin
g
Innovative Therapies
NanoTechnology
Deliv
erin
g
Innovative Therapies
as single therapy, or in combination in
Breast Cancer
Ovarian Cancer
Lung Cancer
Gastric Cancer
Head & Neck Cancer
The first Taxane Approved by FDA for the Adjuvant Treatment of Node Positive Breast Cancer in combination with Standard therapy
The first-line therapy for the treatment of Advanced Ovarian Cancer
The first-line treatment option for advanced or metastatic Non Small Cell Lung Cancer (NSCLC)
elpacPaclitaxel 30 mg, 100 mg & 300 mg Injection
elpac
elpac
The trusted Paclitaxel brand in Bangladesh
Family
L i g h t f o r l i f eRef: Sparano JA, Zhao F, Martino S et al. S3-03. Presented at: San Antonio
Breast Cancer Symposium 2014. Dec. 9-13, 2014; San Antonio, TX.
L i g h t f o r l i f e
nastrol
Anastrozole 1 mg Tablet
nastrolThe therapy of choice for postmenopausal breast cancer
Well tolerated in longterm use
Safe & effective as initial adjuvant therapy for hormone-sensitive postmenopausal early breast cancer
Confirmed event-free and relapse-free survival in early breast cancer patients switching from tamoxifen
Considered as standard first-line treatment for hormonallysensitive postmenopausal advanced breast cancer
Once daily dosing
The breast cancer is curableif it is diagnosed on right time !
L i g h t f o r l i f e
Sister
Mother
Wife
Aunt
Teac
her
Daug
hter
Cous
in
Survi
vor
I will
beat
this
Love
Life
Reme
mber
your
mamm
ogra
m
Take
care
ofyo
urself
I will
not g
iveup
hope
I beli
eve
inm
iracle
s
Never
surre
nder
Supp
ort
Stre
ngth
Heal
ing
Carin
g
Pray
Amen
Mot
ivate
Insp
ire
Cry
Laug
h
Sing
More effective drug compared to other Aromataseinhibitors concerning
Total aromatase inhibitionSuppressing breast cancer tissue and plasma estrogen levelsSuperior overall response rate Superior tolerability and patient preferenceNo Rheumatologic symptoms (Arthralgia or Myalgia) unlike Anastrozole
Guards against breast cancer relapse for up to 8 years
LexelLetrozole USP 2.5 mg Tablet
L i g h t f o r l i f e
Most effective platinum therapy in combination with other approved chemotherapeutic agents
Cisplatin 10 & 50 mg Injection
Metastatic Testicular Tumors
Metastatic Ovarian Tumors
Advanced Bladder Cancer
Non Small Cell Lung Carcinoma
is indicated in
10
L i g h t f o r l i f e
as single therapy, or in combination in
Ovarian cancerCervical CancerBrain TumorSolid TumorAs Bone Marrow Transplant Preparative Regimen
Carboplatin 450 mg & 150 mg Inj.
Beat Ovarian Cancer Effectively
Dosage Guidelines
Single-Agent Therapy :360 mg/m2 by intravenous injection on day 1 every 4 weeks.Combination therapy (with cyclophosphamide):Carboplatin 300 mg/m2 by intravenous injection on day 1 everyfour weeks for six cycles.
200 mg/m2 IV on day 1.The cycle is repeated every 21 days.
300-600 mg/m2 once every 4 weeks.
175 mg/m2 once weekly for 4 weeks with a 2 week recoverybetween courses.
500 mg/m2/day for 3 days.
Ovarian cancer
Cervical Cancer
Solid Tumor
Brain Tumor
As Bone Marrow TransplantPreparative Regimen
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
K-Ras Mutation-Negative, EGFR-Expressing Colorectal Cancer
Focus on target
Cetuximab 100 mg Injection
sttime inBangladesh
L i g h t f o r l i f e
Approved Indications & Dosage
Indication
Metastatic Colorectal Cancer, with IV 5-FU based chemotherapy (for first- or second-line treatment)
Non-squamous Non-Small Cell Lung Cancer (as first line treatment of unresectable, locally advanced, recurrent or metastatic)
Glioblastoma (as second line treatment)
Metastatic Renal Cell Carcinoma (mRCC)
Cervical Cancer
Ovarian Cancer
Dosage
5 mg/kg IV every 2 weeks with bolus-IFL
10 mg/kg IV every 2 weeks with FOLFOX4
5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with Fluoropyrimidine-Irinotecan or Fluoropyrimidine-Oxaliplatin based chemotherapy after progression on a first-line Bevastim containing regimen
15 mg/kg IV every 3 weeks with Carboplatin / Paclitaxel
7.5 mg/kg IV every 3 weeks with Cisplatin Gemcitabine
10 mg/kg IV every 2 weeks as single agent with progressive disease following prior therapy
10 mg/kg IV every 2 weeks with interferonalfa
15 mg/kg every 3 weeks with Paclitaxel and Cisplatin or Paclitaxel and Topotecan
10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks
Date of Approval
2004
January 23, 2013
October 11, 2006
-
May 5, 2009
July 31, 2009
August 14, 2014
Nov 14, 2014
Reference
Study AVF 2107
Study 3200
Phase III ML18147 study
Trial E4599
Asia Pac J Clin Oncol. 2011 Sep;7(3):321
Trials AVF3708g& NCI 06-C-0064E
Trial BO17705
Trial GOG-0240
Phase III TrialAURELIA
Bevacizumab 100 mg & 400 mg Injection
Unique Antiangiogenic Drug
L i g h t f o r l i f e
L i g h t f o r l i f e
Epirubicin Hydrochloride BP 10 mg & 50 mg InjectionErubin
More Effective and Safer Anthracycline therapy
The API of Erubin has been collected from European source and the product quality is confirmed by edQm.
COS* grade of API : More Pure, More Safe
Quality of Medicines & HealthCareEuropean Directorate for the
Increases relapse free & overall survival compared with standard therapiesShorter treatment course with fewer side effectsMore effective and better tolerated than Doxorubicin
A SaferAnthracycline Therapy
L i g h t f o r l i f e
Game Changer inBreast Cancer
1st time manufactured in Bangladesh
XevirolThe Golden Key to Overcome Hormonal Resistance
Everolimus INN 5 mg tablet
Everolimus has been Approved for Breast Cancer by
BUR
EAU
OF FOOD ANDDR
UG
S
DEPARTMENT OF HEALTH
REPUBLIC OF THE PHILIPPIN
ES
BFAD
Swiss
Agen
cy for Therapeutic Products
swissmedic
Advanced Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
Advanced Renal Cell Carcinoma
Advanced Pancreatic Neuroendocrine Tumor (pNET)
US
Usual Dose:10 mg once daily
For Hepatic Impairment patient:
5 mg once daily
For Superior Response:Now considered as 1st Line in CML
1st
Lin
e
L i g h t f o r l i f e
Indication:
Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib.
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
Dasatinib 100 mg tabletDasanix
A new miracle to takeover CML
sttime inBangladesh
Start withConvenientOnce-Daily
Dosing
pill00 mgtime per day
L i g h t f o r l i f e
The Victory in cancer without collateral damage
USFDAapproved
1st line
treatment
in CML
Imatinib 100 mg & 400 mg Tablet
Tailor - made to attack cancer cells
Philadelphia chromosome positiveChronic Myeloid Leukemia (CML)
CML myeloid blast crisis
CML accelerated phase
CML in chronic phase prior/afterInterferon-α therapy
Unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
L i g h t f o r l i f e
The Foundation of Induction Regimen
Daunorubicin 20 mg InjectionRubicin
Acute myeloid leukemia
Acute lymphocytic leukemia
Neuroblastoma
Rhabdomyosarcoma
L i g h t f o r l i f e
An effective drug against a wide range of tumors
Acute lymphoblastic and myeloblastic leukemia
Soft tissue and bone sarcomas
Ovarian carcinoma
Breast cancer
Thyroid carcinoma
Gastric carcinoma
Primary prostatic lymphoma
Hodgkin's disease
Doxorubicin Hydrochloride 10 mg & 50 mgLyophilized Powder for Injection
Ref: J Clin Oncol 32:3824-3830.2014by American Society of Clinical Oncology
Erlotinib 100 mg & 150 mg Tablet
The oral power to fight against NSCLC
As monotherapy in
Treatment of locally advanced or metastatic non-small cell lung cancer
First-line, Second/Third-line treatment of locally advanced or metastatic non-small cell lung cancer
Maintenance treatment of locally advanced or metastatic non-small cell lung cancer
As combination with Gemcitabine (Gemoxen) in
Treatment of locally advanced or metastatic pancreatic cancer
L i g h t f o r l i f e
Inhibits EGFR signal but continues life
time inBangladesh
On the 26 June 2009, The European Commission granted marketing authorisation for Gefitinib for the treatment of adults with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK across all lines of therapy.
National Institute for Health and Clinical Excellence (NICE) recommends Gefitinib as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer patients with EGFR mutation positive.
European Medicines Agency
NHSNational Institute forHealth and Clinical Excellence
L i g h t f o r l i f e
L i g h t f o r l i f e
Highly effective as
Frist line therapy in wild type NSCLC
Second line treatment in EGFR mutated NSCLC
Also effective in combination therapy for the treatment of
Metastatic Prostate Cancer
Advanced Gastric Adenocarcinoma
Advanced Squamous cell Carcinoma
of the Head & Neck
Advanced or Metastatic Breast Cancer
Docetaxel 20 mg & 80 mg Injection
The affordable & dependable docetaxel brand
L i g h t f o r l i f e
Extending the Trust
First-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy.
First-line treatment for inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.
First-line treatment for locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
Treatment of relapsed advanced ovarian cancer in combination with Carboplatin.
Oxaliplatin 50 mg &100 mg Injection
The right weapon to fight against colorectal cancer
Metastatic colorectal cancer
Stage III (Dukes' C) colon cancer after complete resection of primary tumor
as single therapy, or in combination with Fluorouracil / Folinic Acid
or with in
L i g h t f o r l i f e
As monotherapy for the treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline-containingchemotherapy regimen or resistant to paclitaxel.
As first-line treatment of patients with metastatic colorectal carcinoma.
As a single agent for adjuvant treatment in patients with Dukes' C colon cancer.
In combination with docetaxel- for the treatment of metastatic breast cancer after failure of prior anthracycline-containingchemotherapy.
Capecitabine USP 500 mg Tablet
A Unique Oral Option to Boost Survival from Deadly Cancer
Standard
Conf
orm
to International
L i g h t f o r l i f e
L i g h t f o r l i f e
First-line therapy in DLBCL & follicular NHL
Single maintenance therapy after first-line induction in low-grade/follicular NHL
Monotherapy in relapsed/refractory NHL
First-line & Second-line therapy in CLL
Rheumatoid Arthritis who have had an inadequate response to one or more TNF antagonist therapies
The new treatment paradigm for NHL & CLL
Rituximab 100 mg & 500 mg Injection
timemanufactured inBangladesh
L i g h t f o r l i f e
The first & only targeted HER2 therapy proven to increase the chance of living longer both Breast & Gastric Cancer
Recommended for 1 year adjuvant treatment option for early-stage HER2-positive breast cancer
First line treatment of HER2 overexpressing metastatic breast cancer
Also indicated for the treatment of HER2+ metastatic gastric or GEJ cancer who has not received prior treatment for metastatic disease.
TrastunixTrastuzumab 440 mg Injection
A Revolutionary Treatment Option for HER2+ cancers
real breakthrough for
HER2+ cancers
L i g h t f o r l i f e
The Only Approved Systemic Therapy for HCC
Sorafenib 200 mg Tablet
Established Efficacy and Safety in Advanced Hepatocellular carcinoma patients treated > 1 year
The majority of AEs were Grade 1 or 2 and occurred early in therapy
No unexpected or cumulative toxicities occurred with long-term treatment
L i g h t f o r l i f e
FDA Approved first line therapy for mRCC patients
Once daily
Sunitinib 50 mg Capsule
Prolonging survival, reducing toxicity
NCCN Category 1 recommendation as a 1st line treatment for clear-cell mRCC since 2008.
Established in the treatment of advanced RCC with more than 6 years' experience since FDA approval.
Most prescribed among oral medications approved for the treatment of advanced mRCC in the world.
L i g h t f o r l i f e
Refractory Anaplastic Astrocytoma
Newly diagnosed Glioblastoma multiforme
Refractory Glioblastoma multiforme
Temozolomide 100 mg & 250 mg Capsule
The One & Only Standard Treatment Option for GBMs
L i g h t f o r l i f e
Tamoxifen 10 mg & 20 mg Tablet
Tam leThe gold standard drug for estrogen receptor-positive breast cancer
Tam leGold standard treatment for estrogen receptor-positive breast cancer for morethan 30 years
WHO listed essential drug for the treatment of breast cancer
First chemopreventive agent approved by FDA for the reduction of the risk of breast cancer
Inexpensive treatment option for estrogen receptor-positive breast cancer
Extended Duration forGreater Protection
L i g h t f o r l i f e
CytabinCytarabine 100 mg Injection
A Potent Antimetabolite to Cure AML
timemanufactured inBangladesh
Cytarabine is indicated alone or in combination for induction of remission and/or maintenance in patients with
Acute myeloid leukemiaAcute non-lymphoblastic leukemiaAcute lymphoblastic leukemiaAcute lymphocytic leukemiaBlast crisis of chronic myeloid leukemiaDiffuse histiocytic lymphomas (non-Hodgkin's lymphomas of high malignancy)Meningeal leukemiaMeningeal neoplasms
Dosage and Administration:IV/SC: The recommended dose is 100 mg/m2/day (days 1 to 7) or 100 mg/m2 IV every 12 hours (days 1 to 7).
L i g h t f o r l i f e
Vincristine Sulfate 2 mg Injection
Nature's anticancer power
Acute lymphocytic leukemia
Hodgkin's disease
Non-Hodgkin's malignant lymphomas
Rhabdomyosarcoma
Neuroblastoma
L i g h t f o r l i f e
Secure & Reliable Partner
Ifosfamide USP 1 gm & 2 gm Injection
First-line Therapy:
Xifos with anthracyclines is a valid option for symptomatic, locally advanced or inoperable Soft Tissue Sarcomas (STS)
First-line treatment for patients with intermediate or poor-risk Germ Cell Tumors (GCT)
Salvage Therapy:
Conventional-dose Xifos, if patients did not receive it previously.
High-dose Xifos, for those who already received conventional Xifos.
0 Hour 4 Hours 8 Hours Ifosfamide 1.2 gm/m2 - - Mesna 240 mg/m2 240 mg/m2 240 mg/m2
Dose & Administation of Xifos & IfomesMesna is given as intravenous bolus injections in a dosage equal to 20% of the Ifosfamide dosage (%w/w) at the time of Ifosfamide administration and 4 and 8 hours after each dose of Ifosfamide. The total daily dose of Mesna is 60% of the Ifosfamide dose. The recommended dosing schedule is indicated as-
L i g h t f o r l i f e
Lenalidomide INN 10 mg & 25 mg capsule
Fights against hematological malignancy
Multiple Myeloma (MM)
Mantle Cell Lymphoma (MCL)
Myelodysplastic Syndrome (MDS)
L i g h t f o r l i f e
Superior antitumor activity of Irinotecan-based regimen over
best supportive care
As first-line for metastatic Colorectal Cancer (mCRC)As second-line single agent for CRC that has recurred or progressed following Fluorouracil based therapy
Other Uses:
Non Small Cell Lung Cancer2
Recurrent Glioblastoma3
Advanced Ovarian Cancer4
A New Survival Standard for mCRC
Irinotecan Hydrochloride USP 40 mg & 100 mg Injection
L i g h t f o r l i f e
Folinic Acid (Leucovorine) BP 50 mg Injection
50The real choice for synergistic and chemo protective effect
Enhances the anticancer effect of 5-Flurouracil
Rescue therapy during high-dose ofMethotrexate chemotherapy
Provides better therapeutic efficacyin Stomach and Colon cancer